Correct Answer: D. Brimonidine
Brimonidine is an α₂-adrenergic agonist that is contraindicated in infants (<12 months) and young children due to the risk of systemic toxicity and CNS depression. Brimonidine crosses the blood-brain barrier readily in infants because their BBB is immature and less selective. This leads to profound sedation, hypotonia, bradycardia, hypothermia, and apnea—potentially life-threatening in neonates. The FDA issued a black-box warning against brimonidine use in children <2 years, and Indian pediatric ophthalmology guidelines (IAP, AIOC) recommend avoiding it entirely in infants. The drug's high lipophilicity and the infant's reduced hepatic metabolism (CYP3A4 immaturity) compound systemic absorption. In contrast, prostaglandin analogs, beta-blockers (though systemically absorbed), and carbonic anhydrase inhibitors have safer profiles in infants when dosed appropriately, though they still require caution. Brimonidine's selective danger in infants stems from its CNS penetration and the developmental vulnerability of the infant brain.
Why the other options are wrong
A. Latanoprost — Latanoprost, a prostaglandin F₂α analog, is safe in infants and is actually a first-line agent for pediatric glaucoma (congenital, secondary). It acts locally on the eye and has minimal systemic absorption. No black-box warning exists for latanoprost in infants. The trap is that students may confuse it with systemic prostaglandins, which have different safety profiles. B. Timolol — Timolol, a non-selective beta-blocker, is absorbed systemically and can cause bradycardia, bronchospasm, and hypoglycemia in infants—hence it requires caution and dose adjustment. However, it is NOT absolutely contraindicated in infants and is used cautiously in pediatric glaucoma when necessary. The NBE trap: students may conflate 'requires caution' with 'unsafe,' but timolol is not the most dangerous choice here. C. Dorzolamide — Dorzolamide, a topical carbonic anhydrase inhibitor, is safe in infants and is commonly used in pediatric glaucoma management. It acts locally and has minimal systemic absorption when applied topically. Although systemic CAIs (acetazolamide) carry risks in infants, dorzolamide's topical formulation avoids these concerns. The trap is conflating topical and systemic CAI safety profiles.
High-Yield Facts
- Brimonidine is contraindicated in infants (<12 months) due to CNS depression, apnea, and systemic toxicity from immature BBB and reduced hepatic metabolism.
- Prostaglandin analogs (latanoprost, travoprost, bimatoprost) are first-line agents for pediatric glaucoma and are safe in infants with minimal systemic absorption.
- Topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide) are safe in infants; systemic CAIs (acetazolamide) require caution due to metabolic acidosis risk.
- Beta-blockers (timolol) in infants require dose adjustment and monitoring for bradycardia and hypoglycemia but are not absolutely contraindicated.
- Immature blood-brain barrier in infants (<2 years) increases CNS penetration of lipophilic drugs like brimonidine, causing profound sedation and apnea.
Mnemonics
SAFE Pediatric Glaucoma Agents S-Prostaglandin analogs (Safe), A-Acetazolamide (topical dorzolamide, safe), F-First-line latanoprost, E-Exclude brimonidine. Use when counseling parents on which drops are safe for infants. Brimonidine = Brain Risk Brimonidine crosses Briain barrier → Briadycardia, apnea, sedation. Quick recall that alpha-2 agonists are lipophilic and dangerous in immature CNS.
NBE Trap
NBE pairs brimonidine with "antiglaucoma" to test whether students know that not all glaucoma drugs are safe for all ages—a common misconception. Students may assume all topical agents are equally safe, missing the critical developmental pharmacology angle specific to brimonidine's CNS effects in infants.
Clinical Pearl
In Indian pediatric practice, brimonidine-induced apnea and severe bradycardia have been reported in infants presenting to emergency departments after accidental exposure or parental misuse. Always counsel parents that "safe for adults" does not mean "safe for babies"—latanoprost is the go-to first-line drop for congenital and infantile glaucoma in India.
_Reference: KD Tripathi Ch. 12 (Adrenergic Agonists & Antagonists); Harrison Ch. 429 (Glaucoma); IAP Pediatric Ophthalmology Guidelines_